Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194034 | 0.87 | ALDH1A1 (0.54) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL4551268 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL260785 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL6259547 | 0.78 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL2076979 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Maleic Acid SCHEMBL725725 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Fumaric Acid SCHEMBL725726 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL12179926 | 0.77 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| SCHEMBL14538082 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA | |
| Iodide SCHEMBL6303659 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KMT2AMEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | claimed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | claimed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | REVIVO THERAPEUTICS (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2020160541-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | REVIVO THERAPEUTICS (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-2609093-B1 | SALT COMPOUND | SGC PHARMA INC (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170044118-A1 | SALT COMPOUND | SGC PHARMA, INC. (IN) | 2017-02-16 | — | — | US | disclosed |
| US-9114135-B2 | Salt compound | SGC PHARMA INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130245078-A1 | SALT COMPOUND | SGC PHARMA, INC. (CA) | 2013-09-19 | — | — | US | disclosed |
| EP-2609093-A1 | SALT COMPOUND | SGC Pharma Inc. (CA) | 2013-07-03 | — | — | EP | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7189750-B2 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2007-03-13 | — | — | US | disclosed |
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 274/4885KMT2A 3145/4885MEN1 1802/4885 |
| US-20130245078-A1 | SALT COMPOUND | SMN1; SMN2, NLN, BDNF | ALDH1A1 3225/4885KMT2A 2060/4885MEN1 2254/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 202/4885KMT2A 2571/4885MEN1 2519/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | ALDH1A1 240/4885KMT2A 1975/4885MEN1 2443/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 337/4885KMT2A 3551/4885MEN1 1657/4885 |
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | RARS2, RET, PNMT | ALDH1A1 1473/4885KMT2A 152/4885MEN1 52/4885 |
| US-20170044118-A1 | SALT COMPOUND | SMN1; SMN2, NLN, BDNF | ALDH1A1 3013/4885KMT2A 2169/4885MEN1 1779/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 475/4885KMT2A 2960/4885MEN1 2110/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | ALDH1A1 204/4885KMT2A 2758/4885MEN1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.